{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:54:23Z","timestamp":1790214863824,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosurg.","NEUROS"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood brain tumor and the majority of patients die within 2 yr after initial diagnosis. Factors that contribute to the dismal prognosis of these patients include the infiltrative nature and anatomic location in an eloquent area of the brain, which precludes total surgical resection, and the presence of the blood-brain barrier (BBB), which reduces the distribution of systemically administered agents. Convection-enhanced delivery (CED) is a direct infusion technique to deliver therapeutic agents into a target site in the brain and able to deliver a high concentration drug to the infusion site without systemic toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To assess the efficacy of enhancer of zeste homolog-2 (EZH2) inhibitor by CED against human DIPG xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The concentration of EZH2 inhibitor (EPZ-6438) in the brainstem tumor was evaluated by liquid chromatography-mass spectrometry (LC\/MS). We treated mice-bearing human DIPG xenografts with EPZ-6438 using systemic (intraperitoneal) or CED administration. Intracranial tumor growth was monitored by bioluminescence image, and the therapeutic response was evaluated by animal survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      LC\/MS analysis showed that the concentration of EPZ-6438 in the brainstem tumor was 3.74% of serum concentration after systemic administration. CED of EPZ-6438 suppressed tumor growth and significantly extended animal survival when compared to systemic administration of EPZ-6438 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a0.0475).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Our results indicate that CED of an EZH2 inhibitor is a promising strategy to bypass the BBB and to increase the efficacy of an EZH2 inhibitor for the treatment of DIPG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuros\/nyaa301","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T23:24:41Z","timestamp":1592349881000},"page":"E680-E688","source":"Crossref","is-referenced-by-count":24,"title":["Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma"],"prefix":"10.1227","volume":"87","author":[{"given":"Takahiro","family":"Sasaki","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Katagi","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Goldman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Stem Cell Transplantation in the Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren J","family":"Becher","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Stem Cell Transplantation in the Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9373-7831","authenticated-orcid":false,"given":"Rintaro","family":"Hashizume","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12]]},"reference":[{"issue":"6","key":"bib1-20231011","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"5","key":"bib2-20231011","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11910-013-0346-3","article-title":"Brainstem glioma: a review","volume":"13","author":"Grimm","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"bib3-20231011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fonc.2012.00205","article-title":"Diffuse intrinsic pontine glioma: poised for progress","volume":"2","author":"Warren","year":"2012","journal-title":"Front Oncol"},{"key":"bib4-20231011","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fonc.2018.00169","article-title":"The integration of biology into the treatment of diffuse intrinsic pontine glioma: a review of the North American clinical trial perspective","volume":"8","author":"Clymer","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"bib5-20231011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ctrv.2011.06.007","article-title":"Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology","volume":"38","author":"Jansen","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"bib6-20231011","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2005.09.053","article-title":"Barriers to carrier mediated drug and gene delivery to brain tumors","volume":"110","author":"Huynh","year":"2006","journal-title":"J Control Release"},{"issue":"5","key":"bib7-20231011","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/bip.20980","article-title":"Delivery of peptides to the brain: emphasis on therapeutic development","volume":"90","author":"Banks","year":"2008","journal-title":"Biopolymers"},{"key":"bib8-20231011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood-brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"van Tellingen","year":"2015","journal-title":"Drug Resist Updat"},{"key":"bib9-20231011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.00031","article-title":"Treatment strategies in diffuse midline gliomas with the H3K27M mutation: the role of convection-enhanced delivery in overcoming anatomic challenges","volume":"9","author":"Himes","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"bib10-20231011","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/neuonc\/nos305","article-title":"Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts","volume":"15","author":"Chen","year":"2013","journal-title":"Neuro Oncol"},{"issue":"1","key":"bib11-20231011","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/1570159X14666160614093615","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment","volume":"15","author":"Zhou","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"bib12-20231011","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jneumeth.2014.09.020","article-title":"Convection enhanced delivery of carmustine to the murine brainstem: a feasibility study","volume":"238","author":"Sewing","year":"2014","journal-title":"J Neurosci Methods"},{"issue":"3","key":"bib13-20231011","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11060-018-2764-1","article-title":"Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas","volume":"137","author":"Freeman","year":"2018","journal-title":"J Neurooncol"},{"issue":"6","key":"bib14-20231011","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1227\/NEU.0b013e3182233e24","article-title":"Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan","volume":"69","author":"Bruce","year":"2011","journal-title":"Neurosurgery"},{"issue":"3","key":"bib15-20231011","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11060-017-2681-8","article-title":"New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model","volume":"136","author":"Louis","year":"2018","journal-title":"J Neurooncol"},{"issue":"7384","key":"bib16-20231011","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"issue":"3","key":"bib17-20231011","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat Genet"},{"issue":"9","key":"bib18-20231011","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1101\/gad.217778.113","article-title":"The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression","volume":"27","author":"Chan","year":"2013","journal-title":"Genes Dev"},{"issue":"6134","key":"bib19-20231011","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"issue":"10","key":"bib20-20231011","doi-asserted-by":"crossref","first-page":"eaau5935","DOI":"10.1126\/sciadv.aau5935","article-title":"Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma","volume":"4","author":"Stafford","year":"2018","journal-title":"Sci Adv"},{"issue":"4)","key":"bib21-20231011","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nm.4296","article-title":"Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas","volume":"23","author":"Piunti","year":"2017","journal-title":"Nat Med"},{"issue":"4","key":"bib22-20231011","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.4293","article-title":"EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas","volume":"23","author":"Mohammad","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"bib23-20231011","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/embr.201338254","article-title":"Dedifferentiation and reprogramming: origins of cancer stem cells","volume":"15","author":"Friedmann-Morvinski","year":"2014","journal-title":"EMBO Rep"},{"issue":"6","key":"bib24-20231011","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1111\/jcmm.15007","article-title":"Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harboring BRAF(V600E) by synergistically decreasing global trimethylation of H3K27","volume":"24","author":"Fu","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"5","key":"bib25-20231011","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"bib26-20231011","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"bib27-20231011","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"bib28-20231011","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S1470-2045(18)30149-9","article-title":"Targeting EZH2 with tazemetostat","volume":"19","author":"Makita","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"bib29-20231011","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ijc.29566","article-title":"ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors","volume":"137","author":"Zhang","year":"2015","journal-title":"Int J Cancer"},{"issue":"12","key":"bib30-20231011","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nm.3716","article-title":"Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma","volume":"20","author":"Hashizume","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"bib31-20231011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/1570159X14666160523144117","article-title":"Patient-derived tumor models for diffuse intrinsic pontine gliomas","volume":"15","author":"Hashizume","year":"2016","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"bib32-20231011","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11060-012-0973-6","article-title":"Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment","volume":"110","author":"Hashizume","year":"2012","journal-title":"J Neurooncol"},{"issue":"1","key":"bib33-20231011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11060-011-0796-x","article-title":"An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing","volume":"108","author":"Aoki","year":"2012","journal-title":"J Neurooncol"},{"issue":"5","key":"bib34-20231011","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ng.2925","article-title":"Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma","volume":"46","author":"Taylor","year":"2014","journal-title":"Nat Genet"},{"key":"bib35-20231011","first-page":"1992","article-title":"Systemic and local drug delivery for treating diseases of the central nervous system in rodent models","volume":"42","author":"Serwer","year":"2010","journal-title":"J Vis Exp"},{"issue":"2","key":"bib36-20231011","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1634\/theoncologist.5-2-144","article-title":"Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma","volume":"5","author":"Agarwala","year":"2000","journal-title":"Oncologist"},{"key":"bib37-20231011","article-title":"FDA places partial clinical hold on tazemetostat trials","author":""},{"issue":"12","key":"bib38-20231011","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2217\/nnm.12.209","article-title":"Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models","volume":"8","author":"Weng","year":"2013","journal-title":"Nanomedicine"},{"key":"bib39-20231011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.wneu.2020.01.199","article-title":"Longitudinal monitoring of Gd-DTPA following convection enhanced delivery in the brainstem","volume":"137","author":"Tosi","year":"2020","journal-title":"World Neurosurg"}],"container-title":["Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neurosurgery\/article-pdf\/87\/6\/E680\/41162248\/nyaa301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyaa301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:56:32Z","timestamp":1786121792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1093\/neuros\/nyaa301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1093\/neuros\/nyaa301","relation":{},"ISSN":["0148-396X","1524-4040"],"issn-type":[{"value":"0148-396X","type":"print"},{"value":"1524-4040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}